Better feasibility starts before the protocol is finalized. Phase I oncology trials can face enrollment delays, amendments and execution challenges when protocols don’t fully account for real-world site and patient realities.

In this expert-led session, learn how early investigator and site input can uncover hidden feasibility risks and help shape protocols that balance scientific rigor with operational execution. Drawing on expertise from IQVIA Biotech and IQVIA, alongside a leading NEXT Oncology investigator, this panel of early-phase oncology and site strategy experts will share practical insights for improving enrollment viability, data quality and execution confidence from the outset.

Key takeaways

• Recognize protocol red flags that can lead to avoidable amendments and delays in FIH oncology trials
• Learn how early investigator and site input can identify hidden feasibility risks
• Understand how structured early engagement can support faster, more confident trial execution

Panel

• Kristin Zorn, M.D., Senior Medical Director, Medical Strategy Lead, IQVIA Oncology Center of Excellence
• Jennifer Segar, M.D., Senior Clinical Investigator, NEXT Oncology Houston
• Bridget Weeks, Director of Project Management, Oncology

Learn more, visit the registration page.